Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Relapsed or Refractory Cutaneous T-cell Lymphoma
CTR20130112Phase 2Completed
- Sponsor
- Jilin Yixin Pharmaceutical
- Start
- Apr 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Jilin Yixin Pharmaceutical. Started Apr 2014; status: completed.
02
Drugs
vorinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on CTR20130112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130112.